Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP170672.RAVlHC3FTpciS8B5u_EN4zF1HFO7WhufeGwmY_r2EsTXM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP170672.RAVlHC3FTpciS8B5u_EN4zF1HFO7WhufeGwmY_r2EsTXM130_assertion type Assertion NP170672.RAVlHC3FTpciS8B5u_EN4zF1HFO7WhufeGwmY_r2EsTXM130_head.
- NP170672.RAVlHC3FTpciS8B5u_EN4zF1HFO7WhufeGwmY_r2EsTXM130_assertion description "[Of the 80 specimens of primary prostate cancer examined by receptor binding assays, 50 ( approximately 63%) showed high-affinity, low-capacity binding sites for bombesin/GRP, and 12 of these 50 receptor-positive specimens also showed a second binding site.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP170672.RAVlHC3FTpciS8B5u_EN4zF1HFO7WhufeGwmY_r2EsTXM130_provenance.
- NP170672.RAVlHC3FTpciS8B5u_EN4zF1HFO7WhufeGwmY_r2EsTXM130_assertion evidence source_evidence_literature NP170672.RAVlHC3FTpciS8B5u_EN4zF1HFO7WhufeGwmY_r2EsTXM130_provenance.
- NP170672.RAVlHC3FTpciS8B5u_EN4zF1HFO7WhufeGwmY_r2EsTXM130_assertion SIO_000772 10679759 NP170672.RAVlHC3FTpciS8B5u_EN4zF1HFO7WhufeGwmY_r2EsTXM130_provenance.
- NP170672.RAVlHC3FTpciS8B5u_EN4zF1HFO7WhufeGwmY_r2EsTXM130_assertion wasDerivedFrom befree-20140225 NP170672.RAVlHC3FTpciS8B5u_EN4zF1HFO7WhufeGwmY_r2EsTXM130_provenance.
- NP170672.RAVlHC3FTpciS8B5u_EN4zF1HFO7WhufeGwmY_r2EsTXM130_assertion wasGeneratedBy ECO_0000203 NP170672.RAVlHC3FTpciS8B5u_EN4zF1HFO7WhufeGwmY_r2EsTXM130_provenance.